TICKERNERD
Menu
RVMDRVMDHealthcare · Biotechnology

RVMD Stock Forecast: Revolution Medicines, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$204
+0.23% on the day

The 21 Wall Street analysts covering Revolution Medicines, Inc. hold a median 12-month price target of $250 — +22.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$43.6B
Ticker Nerd rank
40 / 100
Median analyst target
$250
Analysts covering
21
Revenue$0.0
Operating income−$505.1M
Net income−$644.4M
Free cash flow−$745.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
−0.8%
YTD
+155.9%
1Y
+340.8%
From 52W high
−7.8%
From 52W low
+379.5%
$43
$221
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RVMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Revolution Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
89
Volatility
58
Accruals
58
Revisions
46
Quality
46
Growth
27
Issuance
9
Size
6

Momentum (100): The shares have been drifting up relative to others.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RVMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RVMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250$300$350Oct 25Jan 26Apr 26Jul 26RVMDHigh $320Median $250Low $179

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
20 Buy1 Hold0 Sell
Low $179Median $250High $320

The green dot is the last close — the median target sits +22.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 15 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Sept 2026Morgan StanleyInitiatesOverweight$255
9 Sept 2026StifelMaintainsBuy$215 → $230
31 Aug 2026NeedhamMaintainsBuy$240 → $275
28 Aug 2026GuggenheimMaintainsBuy$240 → $275
28 Aug 2026UBSMaintainsBuy$220 → $265
27 Aug 2026Evercore ISI GroupMaintainsOutperform$230 → $320
27 Aug 2026HC Wainwright & Co.MaintainsBuy$195 → $280
27 Aug 2026OppenheimerMaintainsOutperform$230 → $260
27 Aug 2026RBC CapitalMaintainsOutperform$203 → $251
27 Aug 2026Truist SecuritiesMaintainsBuy$231 → $239
27 Aug 2026WedbushMaintainsOutperform$201 → $225
21 Aug 2026BernsteinMaintainsMarket Perform—
21 Aug 2026BernsteinMaintainsMarket Perform$151 → $179
11 Aug 2026Truist SecuritiesMaintainsBuy$210 → $231
11 Aug 2026Truist SecuritiesMaintainsBuy—
6 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 Aug 2026Evercore ISI GroupMaintainsOutperform$220 → $230
6 Aug 2026GuggenheimMaintainsBuy—
6 Aug 2026GuggenheimMaintainsBuy$235 → $240
6 Aug 2026NeedhamMaintainsBuy$236 → $240

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RVMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Revolution Medicines, Inc. returned +340.8% against +17.5% for the S&P 500, dividends included.

RVMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26RVMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RVMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
18
Fundamentals

Revolution Medicines, Inc. (RVMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−34.2×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
16.7×

Cheaper than 6% of US stocks

EV / EBITDA
−25.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−79.1%

Higher than 16% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Revolution Medicines, Inc. (RVMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Revolution Medicines, Inc. has a market value of $43.6B and an enterprise value of $41.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$1.8B.

  • Diluted earnings per share, trailing twelve months: $−8.82.

  • Free cash flow in the twelve months to 30 June 2026: −$1.6B.

  • Shares outstanding: 214.2M.

  • Trailing P/E: −34.2×; forward P/E: −34.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Revolution Medicines, Inc. employs 883 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

RVMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RVMDRevolution Medicines, Inc.$43.6B
40
RPRXRoyalty Pharma plc$33.8B
87
ALNYAlnylam Pharmaceuticals, Inc.$32.9B
50
MRNAModerna, Inc.$57.5B
82
ROIVRoivant Sciences Ltd.$29.2B
38
INSMInsmed, Inc.$28.3B
85
INCYIncyte Corp.$24.3B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Revolution Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RVMD news & analysis

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 11 Sept 2026neutral

A Motley Fool article compares Amgen and Revolution Medicines as healthcare stock picks for 2026, noting Amgen's large global footprint and over $8.1 billion in free cash flow while describing Revolution Medicines as a clinical-stage oncology specialist focused on breakthrough therapies for RAS-addicted cancers.

Why it matters — An RVMD watcher would care because the article positions the company as a clinical-stage oncology specialist developing therapies for RAS-addicted cancers, offering a profile comparison against an established large-cap peer.

Revolution Medicines Got Its Breakthrough—What Moves It Next?

MarketBeat · 4 Sept 2026positive

On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, marking one of the largest oncology wins of the year for Revolution Medicines. Despite the approval, the stock saw only modest movement.

Why it matters — RVMD watchers would care because the FDA approval of its first broad RAS-targeted therapy is a major regulatory milestone that establishes the company's position in a significant oncology market.

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 4 Sept 2026positive

Revolution Medicines reported its earnings 30 days ago, and since that report the company's stock has risen 6.6%. The article examines what may come next for the stock following that earnings report.

Why it matters — RVMD watchers would care because the article assesses the stock's recent upward movement since the last earnings report and looks at what might lie ahead for the company.

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GlobeNewsWire · 2 Sept 2026positive

The New England Journal of Medicine published data from Revolution Medicines' Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral RAS(ON) multi-selective inhibitor, in previously treated patients with advanced RAS mutant non-small cell lung cancer. The publication highlights clinical data for the company's pipeline candidate in metastatic NSCLC.

Why it matters — Publication in a leading peer-reviewed medical journal brings additional visibility and validation to a key clinical asset in Revolution Medicines' oncology pipeline for RAS-addicted cancers.

Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions

Seeking Alpha · 31 Aug 2026positive

Revolution Medicines received FDA approval for RASONQUE in second-line metastatic pancreatic ductal adenocarcinoma (PDAC), with its pipeline including zoldonrasib targeting G12D-mutant PDAC and NSCLC and two pivotal phase 3 trials underway in first-line settings. The company reports $3.9B in cash, supported by recent financings and a $2B agreement with Royalty Pharma, providing at least 12 months of operational runway.

Why it matters — A RVMD watcher would care because the FDA approval of RASONQUE and the advancing zoldonrasib phase 3 program represent key clinical milestones for the company's pipeline in PDAC and NSCLC.

FAQ

Frequently asked questions about RVMD stock

What is the RVMD stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Revolution Medicines, Inc. have a median 12-month price target of $250, with estimates ranging from $179 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RVMD stock a buy right now?

Of the 21 analysts covering Revolution Medicines, Inc., 20 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revolution Medicines, Inc. 40 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RVMD?

As at 12 Sept 2026, Revolution Medicines, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will RVMD stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +22.4% from the last close, and Ticker Nerd's factor model ranks Revolution Medicines, Inc. 40 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RVMD stock forecast for 2030?

No analyst covering Revolution Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $179 to $320 over the next 12 months.

How has RVMD stock performed over the past year?

Revolution Medicines, Inc. returned +340.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Revolution Medicines, Inc. do?

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers.

What is the latest news on RVMD?

The most recent item we track (The Motley Fool, 11 Sept 2026): "Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?". A Motley Fool article compares Amgen and Revolution Medicines as healthcare stock picks for 2026, noting Amgen's large global footprint and over $8.1 billion in free cash flow while describing Revolution Medicines as a clinical-stage oncology specialist focused on breakthrough therapies for RAS-addicted cancers.

Company

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.

CEO Dr. Mark A. Goldsmith M.D., Ph.D. · 883 employees · United States · https://www.revmed.com